Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Relationship Between Increased Fucosylation and Metastatic Potential in Colorectal Cancer.
Osuga T, Takimoto R, Ono M, Hirakawa M, Yoshida M, Okagawa Y, Uemura N, Arihara Y, Sato Y, Tamura F, Sato T, Iyama S, Miyanishi K, Takada K, Hayashi T, Kobune M, Kato J. Osuga T, et al. Among authors: takimoto r. J Natl Cancer Inst. 2016 Sep 14;108(9):djw210. doi: 10.1093/jnci/djw210. Print 2016 Sep. J Natl Cancer Inst. 2016. PMID: 27628655 Retracted.
RNAi-mediated gene silencing of ST6GalNAc I suppresses the metastatic potential in gastric cancer cells.
Tamura F, Sato Y, Hirakawa M, Yoshida M, Ono M, Osuga T, Okagawa Y, Uemura N, Arihara Y, Murase K, Kawano Y, Iyama S, Takada K, Hayashi T, Sato T, Miyanishi K, Kobune M, Takimoto R, Kato J. Tamura F, et al. Among authors: takimoto r. Gastric Cancer. 2016 Jan;19(1):85-97. doi: 10.1007/s10120-014-0454-z. Epub 2014 Dec 23. Gastric Cancer. 2016. PMID: 25532910
A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer.
Sato Y, Ohnuma H, Hirakawa M, Takahashi M, Osuga T, Okagawa Y, Murase K, Takada K, Kawano Y, Iyama S, Hayashi T, Sato T, Miyanishi K, Takimoto R, Kobune M, Okita K, Mizuguchi T, Furuhata T, Hirata K, Kato J. Sato Y, et al. Among authors: takimoto r. Cancer Chemother Pharmacol. 2015 Mar;75(3):587-94. doi: 10.1007/s00280-014-2672-9. Epub 2015 Jan 11. Cancer Chemother Pharmacol. 2015. PMID: 25577134 Clinical Trial.
Relationship Between Increased Fucosylation and Metastatic Potential in Colorectal Cancer.
Osuga T, Takimoto R, Ono M, Hirakawa M, Yoshida M, Okagawa Y, Uemura N, Arihara Y, Sato Y, Tamura F, Sato T, Iyama S, Miyanishi K, Takada K, Hayashi T, Kobune M, Kato J. Osuga T, et al. Among authors: takimoto r. J Natl Cancer Inst. 2016 Apr 13;108(8):djw038. doi: 10.1093/jnci/djw038. Print 2016 Aug. J Natl Cancer Inst. 2016. PMID: 27075853 Free PMC article.
Targeting Notch-1 positive acute leukemia cells by novel fucose-bound liposomes carrying daunorubicin.
Ono M, Takimoto R, Osuga T, Okagawa Y, Hirakawa M, Yoshida M, Arihara Y, Uemura N, Hayasaka N, Miura S, Matsuno T, Tamura F, Sato Y, Sato T, Iyama S, Miyanishi K, Takada K, Kobune M, Kato J. Ono M, et al. Among authors: takimoto r. Oncotarget. 2016 Jun 21;7(25):38586-38597. doi: 10.18632/oncotarget.9558. Oncotarget. 2016. PMID: 27233074 Free PMC article.
A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
Hirakawa M, Sato Y, Ohnuma H, Takayama T, Sagawa T, Nobuoka T, Harada K, Miyamoto H, Sato Y, Takahashi Y, Katsuki S, Hirayama M, Takahashi M, Ono M, Maeda M, Takada K, Hayashi T, Sato T, Miyanishi K, Takimoto R, Kobune M, Hirata K, Kato J. Hirakawa M, et al. Among authors: takimoto r. Cancer Chemother Pharmacol. 2013 Mar;71(3):789-97. doi: 10.1007/s00280-013-2073-5. Epub 2013 Jan 22. Cancer Chemother Pharmacol. 2013. PMID: 23338051 Clinical Trial.
199 results